Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA

As the most common mutation in papillary thyroid cancer (PTC), B-type Raf kinase V600E mutation (BRAF(V600E)) has become an important target for the clinical treatment of PTC. However, the clinical application still faces the problem of resistance to BRAF inhibitors (BRAFi). Therefore, exploring BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, YaLi, Yu, XiaQing, Yin, YuZhen, Lv, Zhongwei, Jia, ChengYou, Liao, Yina, Sun, Hongyan, Liu, Tie, Cong, Lele, Fei, ZhaoLiang, Fu, Da, Cong, Xianling, Qu, Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890315/
https://www.ncbi.nlm.nih.gov/pubmed/33613767
http://dx.doi.org/10.7150/jca.51551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890315/
https://www.ncbi.nlm.nih.gov/pubmed/33613767
http://dx.doi.org/10.7150/jca.51551

Ejemplares similares